(redirected from Direct thrombin inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
See: deterrent
References in periodicals archive ?
The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial.
Randomized, double-blind, comparative study of ximelagatran (pINN, formerly H 376/95), an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee arthroplasty (TKA) [Abstract OC 44].
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
UFH therapy should be immediately discontinued and replaced by a direct thrombin inhibitor.
Andreas Barner, Member of the Board of Boehringer Ingelheim and responsible for Research, Development and Medicine worldwide said, "We are pleased that our new oral direct thrombin inhibitor, dabigatran, has demonstrated it could fulfil the current unmet medical need for an anticoagulant that can easily be taken by orthopaedic patients also once they have left hospital, thereby continuing to protect them from a life-threatening thrombus.
Dabigatran etexilate is a reversible oral direct thrombin inhibitor, a novel oral anticoagulant in advanced development.
Product Profiles of the Major Marketed Products in Venous Thromboembolism Market - Direct Thrombin Inhibitor Class
Dabigatran etexilate is a promising new oral direct thrombin inhibitor that specifically and reversibly inhibits thrombin, the key enzyme for blood clot formation.
SAN DIEGO -- Treatment to prevent recurrent deep vein thrombosis using the direct thrombin inhibitor, ximelagatran, was equivalent to enoxaparin and warfarin over 6 months, Dr.
Ximelagatran, a direct thrombin inhibitor that is most like warfarin, is administered orally, with onset of action at 2 hours vs.
CHICAGO--Results of the largest-ever clinical trial of stroke prevention in atrial fibrillation show compelling advantages for ximelagatran, an oral direct thrombin inhibitor, over warfarin.